


Supplementary material



Forest plot of comparison between regorafenib *versus* placebo; the outcome was relative risk of serious adverse events (SAEs). CI: Confidence interval.

PubMed electronic search strategy:

(Regorafenib[title] OR Stivarga[title] OR BAY 73-4506[title]) AND (phase 2 trial[title]) OR (phase 3 trial[title])